新型大麻素 CBG 衍生物可减轻炎症、疼痛和肥胖。

Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity.

机构信息

Medical Faculty, Institute for Drug Research, Hebrew University, Jerusalem 91120, Israel.

Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.

出版信息

Molecules. 2021 Sep 15;26(18):5601. doi: 10.3390/molecules26185601.

Interest in CBG (cannabigerol) has been growing in the past few years, due to its anti-inflammatory properties and other therapeutic benefits. Here we report the synthesis of three new CBG derivatives (HUM-223, HUM-233 and HUM-234) and show them to possess anti-inflammatory and analgesic properties. In addition, unlike CBG, HUM-234 also prevents obesity in mice fed a high-fat diet (HFD). The metabolic state of the treated mice on HFD is significantly better than that of vehicle-treated mice, and their liver slices show significantly less steatosis than untreated HFD or CBG-treated ones from HFD mice. We believe that HUM-223, HUM-233 and HUM-234 have the potential for development as novel drug candidates for the treatment of inflammatory conditions, and in the case of HUM-234, potentially for obesity where there is a huge unmet need.

在过去的几年中，由于其具有抗炎特性和其他治疗益处，人们对 CBG（大麻素二醇）的兴趣日益浓厚。在这里，我们报告了三种新型 CBG 衍生物（HUM-223、HUM-233 和 HUM-234）的合成，并证明它们具有抗炎和镇痛作用。此外，与 CBG 不同，HUM-234 还可以预防高脂肪饮食（HFD）喂养的小鼠肥胖。接受治疗的 HFD 小鼠的代谢状态明显好于接受载体治疗的小鼠，其肝切片的脂肪变性明显少于未经处理的 HFD 或来自 HFD 小鼠的 CBG 处理的肝切片。我们相信 HUM-223、HUM-233 和 HUM-234 有可能成为治疗炎症性疾病的新型候选药物，而对于 HUM-234，在肥胖症方面也有巨大的未满足的需求。